''It's a bit of a miracle, given there were no competing bids, [and] an independent report by Deloitte valued it at $3.55 a share,''Shareholders need to remember that it is almost impossible to accept an offer that hasn't made, unless of course they were going to source the offer from their own finances. That would almost certainly require another miracle.
Shareholders need to consider that by accepting the revised offer the market now knows that CST is worth a minimum of $3.80 and the option of picking up the company at a bargain price post a failed SofA has been swept off the table. By raising the offer Qiagen has signalled to the market that Qiagen really want CST and should there be another interested party the only option left to them would be to make a competing bid and to make it real fast.
